Genzyme Corp.

Genzyme Corporation, commonly known as Genzyme, was an American biotechnology company founded in 1981 in Boston, Massachusetts, and headquartered in Cambridge, Massachusetts. In 2011, Genzyme was acquired by French pharmaceutical giant Sanofi for $20.1 billion, becoming a wholly-owned subsidiary. By 2010, prior to its acquisition, Genzyme was the world's third-largest biotechnology company, employing over 11,000 people globally and generating over $4 billion in revenue. As a Sanofi entity, "Sanofi Genzyme" was reported to have 10,100 to 12,000 employees. In February 2022, Sanofi integrated the "Sanofi Genzyme" entity into its overarching corporate brand.

Genzyme focused on developing and delivering transformative therapies, particularly for rare inherited disorders like lysosomal storage diseases. Key product offerings included Cerezyme for Gaucher disease, Fabrazyme for Fabry's disease, Renagel for renal disease patients, Synvisc for osteoarthritis knee pain, and Myozyme/Lumizyme for Pompe disease. The company also had a presence in diagnostic products and services, pharmaceutical and fine chemicals, orthopedics, oncology, and transplant and immune diseases.

Genzyme's patent litigation posture indicates it is an operating company defending its intellectual property. The company is listed as a defendant in two tracked cases before the Patent Trial and Appeal Board (PTAB), both initiated by Unified Patents. These challenges typically aim to invalidate existing patents held by Genzyme.

Beyond the tracked PTAB cases, Genzyme has been involved in other significant patent disputes. For instance, the company successfully defended its recombinant adeno-associated virus vector technology against infringement actions by Novartis Gene Therapies, Inc. and was involved in Genzyme Therapeutic Prods. v. Biomarin Pharms., where the Federal Circuit affirmed PTAB decisions invalidating some of Genzyme's patents. These cases underscore Genzyme's role as an active participant in patent-related legal proceedings, protecting and defending its biopharmaceutical innovations.